Theralink Technologies, Inc.
Theralink Technologies, Inc.
Your view on THER
Overview
What the company does, where it operates, and who runs it.
About Theralink Technologies, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael I. Ruxin
- Headquarters
- 15000 West 6th Avenue, Golden, CO, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael I. Ruxin
- Headquarters
- 15000 West 6th Avenue, Golden, CO, US
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products.
The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development.
It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments.
The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020.
The company is headquartered in Golden, Colorado.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Theralink Technologies, Inc., and the rating behind it. THER last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Theralink Technologies, Inc.. Starting points for Theralink Technologies, Inc.: EPS -$0.50, beta 8.99 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Theralink Technologies, Inc.. Theralink Technologies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Theralink Technologies, Inc.. Trailing twelve-month EPS for Theralink Technologies, Inc. stands at -$0.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Theralink Technologies, Inc.. Theralink Technologies, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Theralink Technologies, Inc. valued side by side against its closest peers. Theralink Technologies, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Theralink Technologies, Inc., and how their positions are changing. At a $615,149 market value, institutional positions materially move Theralink Technologies, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Theralink Technologies, Inc. executives and directors. Shares of Theralink Technologies, Inc. have traded between $0.0001 and $0.0010 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Theralink Technologies, Inc.. Theralink Technologies, Inc. is a $615,149 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Theralink Technologies, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Theralink Technologies, Inc.. Coverage tracks Theralink Technologies, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.